NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free CVKD Stock Alerts $0.41 -0.01 (-2.38%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$0.41▼$0.4350-Day Range$0.39▼$0.6552-Week Range$0.36▼$3.14Volume57,112 shsAverage Volume120,836 shsMarket Capitalization$6.57 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cadrenal Therapeutics alerts: Email Address Cadrenal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside752.4% Upside$3.50 Price TargetShort InterestHealthy0.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.04 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cadrenal Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.80% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently decreased by 60.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVKD. Previous Next 2.7 News and Social Media Coverage News SentimentCadrenal Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cadrenal Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders58.12% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.92% of the stock of Cadrenal Therapeutics is held by institutions.Read more about Cadrenal Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cadrenal Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Cadrenal Therapeutics Stock (NASDAQ:CVKD)Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Read More CVKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVKD Stock News HeadlinesMay 23 at 9:00 AM | prnewswire.comCadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cadrenal Therapeutics on Strong Clinical and Financial ProspectsMay 9, 2024 | prnewswire.comCadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateApril 20, 2024 | finance.yahoo.comFavourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired StockApril 11, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | prnewswire.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | marketwatch.comCadrenal Therapeutics Gets FDA Orphan Drug Designation for TecarfarinApril 9, 2024 | markets.businessinsider.comCadrenal Therapeutics: FDA Grants Orphan Drug Designation For Tecarfarin; Stock JumpsApril 9, 2024 | bizjournals.comPonte Vedra-based Cadrenal Therapeutics receives second FDA orphan drug designationApril 9, 2024 | prnewswire.comCadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsMarch 14, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)March 11, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateMarch 11, 2024 | finance.yahoo.comCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateFebruary 26, 2024 | prnewswire.comCadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceFebruary 14, 2024 | morningstar.comCadrenal Therapeutics Inc CVKDFebruary 8, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialFebruary 8, 2024 | finance.yahoo.comCadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialJanuary 31, 2024 | finance.yahoo.comCadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsJanuary 30, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn SituationJanuary 24, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 4, 2024 | finance.yahoo.comCadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceDecember 19, 2023 | benzinga.comCadrenal Therapeutics Stock (NASDAQ:CVKD), Analyst Ratings, Price Targets, PredictionsDecember 11, 2023 | uk.finance.yahoo.comCadrenal Therapeutics, Inc. (CVKD)November 30, 2023 | finance.yahoo.comCadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023November 21, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Cadrenal Therapeutics (CVKD) with Buy RecommendationSee More Headlines Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/25/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVKD CUSIPN/A CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+752.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.11% Return on Assets-68.16% Debt Debt-to-Equity RatioN/A Current Ratio8.21 Quick Ratio8.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book1.05Miscellaneous Outstanding Shares16,010,000Free Float6,704,000Market Cap$6.57 million OptionableNot Optionable Beta1.64 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Douglas W. Losordo FACC (Age 66)FAHA, M.D., Chief Medical Officer Comp: $528.69kMr. Quang X. Pham (Age 59)Chairman & CEO Comp: $822.17kMr. Matthew K. Szot CPA (Age 50)CPA, Chief Financial Officer Comp: $359.61kMr. Jeffrey ColeChief Operating OfficerKey CompetitorsEnlivex TherapeuticsNASDAQ:ENLVAcasti PharmaNASDAQ:ACSTUnity BiotechnologyNASDAQ:UBXTherapeuticsMDNASDAQ:TXMDLisata TherapeuticsNASDAQ:LSTAView All CompetitorsInsidersJohn Raymond MurphyBought 17,331 shares on 10/4/2023Total: $12,131.70 ($0.70/share)Quang X PhamBought 70,000 shares on 9/1/2023Total: $63,700.00 ($0.91/share)View All Insider Transactions CVKD Stock Analysis - Frequently Asked Questions Should I buy or sell Cadrenal Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cadrenal Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVKD shares. View CVKD analyst ratings or view top-rated stocks. What is Cadrenal Therapeutics' stock price target for 2024? 2 brokers have issued 12-month price objectives for Cadrenal Therapeutics' stock. Their CVKD share price targets range from $3.00 to $4.00. On average, they predict the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 752.4% from the stock's current price. View analysts price targets for CVKD or view top-rated stocks among Wall Street analysts. How have CVKD shares performed in 2024? Cadrenal Therapeutics' stock was trading at $0.7399 on January 1st, 2024. Since then, CVKD shares have decreased by 44.5% and is now trading at $0.4106. View the best growth stocks for 2024 here. When is Cadrenal Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CVKD earnings forecast. How were Cadrenal Therapeutics' earnings last quarter? Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering on Friday, January 20th 2023. The company issued 1,400,000 shares at a price of $5.00 per share. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVKD) was last updated on 5/25/2024 by MarketBeat.com Staff From Our PartnersThis could mean the end of the U.S dollar…Colonial MetalsThe 1,000X Crypto PlaybookTrue Market InsidersBiden FINISHED On June 13th?Paradigm PressWrite this ticker symbol down…StocksToTradeHooray! 97% OFF for the Memorial Day SaleStockEarningsJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
